Kenneth Duncan joined Accent in January 2020 as Vice President of Chemistry, bringing more than 20 years of biotech drug discovery experience. He has contributed to eight clinical drug candidates over his career, so far resulting in one approval. Prior to joining Accent, Kenneth served as Vice President of Medicinal Chemistry at Epizyme and previously, with a number of biotech firms, including Antisoma, Infinity, and Cyclacel on a range of oncology and non-oncology indications. Kenneth received his BSc and PhD from the University of Strathclyde in Glasgow, Scotland.